Weaver Capital Management LLC Has $1.31 Million Stake in Stryker Co. (NYSE:SYK)

Weaver Capital Management LLC increased its position in Stryker Co. (NYSE:SYK) by 4.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,630 shares of the medical technology company’s stock after acquiring an additional 159 shares during the quarter. Weaver Capital Management LLC’s holdings in Stryker were worth $1,307,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in SYK. Czech National Bank increased its stake in shares of Stryker by 8.1% in the third quarter. Czech National Bank now owns 69,843 shares of the medical technology company’s stock valued at $25,231,000 after buying an additional 5,235 shares during the period. GAMMA Investing LLC increased its stake in shares of Stryker by 38.7% in the third quarter. GAMMA Investing LLC now owns 2,901 shares of the medical technology company’s stock valued at $1,048,000 after buying an additional 810 shares during the period. Miracle Mile Advisors LLC increased its stake in shares of Stryker by 569.2% in the third quarter. Miracle Mile Advisors LLC now owns 5,983 shares of the medical technology company’s stock valued at $2,161,000 after buying an additional 5,089 shares during the period. Bath Savings Trust Co increased its stake in shares of Stryker by 0.4% in the third quarter. Bath Savings Trust Co now owns 112,589 shares of the medical technology company’s stock valued at $40,674,000 after buying an additional 423 shares during the period. Finally, Versant Capital Management Inc increased its stake in shares of Stryker by 11.3% in the third quarter. Versant Capital Management Inc now owns 962 shares of the medical technology company’s stock valued at $348,000 after buying an additional 98 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Trading Up 0.4 %

Shares of Stryker stock opened at $392.55 on Wednesday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The stock has a fifty day moving average price of $376.81 and a 200-day moving average price of $363.64. The firm has a market cap of $149.65 billion, a PE ratio of 50.59, a P/E/G ratio of 2.78 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter last year, the firm posted $3.46 earnings per share. Equities research analysts anticipate that Stryker Co. will post 13.5 EPS for the current year.

Stryker Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st were paid a $0.84 dividend. The ex-dividend date was Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.86%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is currently 43.30%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. BTIG Research upped their price objective on Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. Stifel Nicolaus upped their target price on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. UBS Group upped their target price on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. upped their target price on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, The Goldman Sachs Group upped their target price on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a report on Thursday, January 30th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $419.37.

Insiders Place Their Bets

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction that occurred on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now owns 100,027 shares of the company’s stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.50% of the stock is owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.